US5773474A - Potent inducers of terminal differentiation and method of use thereof - Google Patents
Potent inducers of terminal differentiation and method of use thereof Download PDFInfo
- Publication number
- US5773474A US5773474A US08/485,620 US48562095A US5773474A US 5773474 A US5773474 A US 5773474A US 48562095 A US48562095 A US 48562095A US 5773474 A US5773474 A US 5773474A
- Authority
- US
- United States
- Prior art keywords
- compound
- amount
- cells
- independently
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000011712 cell development Effects 0.000 title claims abstract description 18
- 239000000411 inducer Substances 0.000 title description 4
- 230000003389 potentiating effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 210000004027 cell Anatomy 0.000 claims abstract description 32
- 210000005170 neoplastic cell Anatomy 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 230000035755 proliferation Effects 0.000 claims abstract description 13
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 4
- 230000001988 toxicity Effects 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 101100177155 Arabidopsis thaliana HAC1 gene Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 239000000203 mixture Chemical class 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101150108015 STR6 gene Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- MRNZSTMRDWRNNR-UHFFFAOYSA-N bis(hexamethylene)triamine Chemical compound NCCCCCCNCCCCCCN MRNZSTMRDWRNNR-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/28—Two oxygen or sulfur atoms
- C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
- C07D231/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
Definitions
- Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation.
- chemotherapeutic treatment of cancer a) blocking hormone-dependent tumor cell proliferation by interference with the production or peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations.
- cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (10).
- cyclic AMP and retinoic acid (1,2)
- aclarubicin and other anthracyclines (3)
- polar planar compounds of which the most extensively studied is hexamethylene bisacetamide (HMBA) (4-5, 9).
- HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cell lines (6).
- the characteristics of the drug-induced effect have been most extensively studied in the Friend murine erythroleukemia cell system (MELC) (6-9).
- MELC induction of differentiation is both time and concentration dependent.
- the minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.
- the present invention provides new chemical inducers which are 2-5 times more active then HMBA. It has unexpectedly been found that compounds having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound are effective inducers of terminal differentiation. For instance, bis-hexamethylene triacetamide, which comprises three acetamide groups connected by two six-carbon chains, has been found to be a potent inducer of terminal differentiation in MELC.
- This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.
- the invention provides a class of compounds having the structure:
- each of A, A 1 , A 2 , A 3 , and A 4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom and wherein each of A, A 1 , A 2 , A 3 , and A 4 may independently be the same as, or different from, the others of A, A 1 , A 2 , A 3 , and A 4 ;
- each of R and R 1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure: ##STR3## each of R 2 and R 3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R 1 , R 2 and R 3 may independently be the same as, or different from, the others of R, R 1 , R 2 and R 3 ;
- each of R-A! and A 4 -R 1 ! have a dipolar moment greater than about 2.7 Debye units;
- each of B, B 1 , B 2 , and B 3 represents a nonpolar group which comprises at least 4 atoms in a chain, the termini of which chains are attached to A and A 1 , A 1 and A 2 , A 2 and A 3 , and A 3 and A 4 , respectively; wherein each such atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B 1 , B 2 , and B 3 may independently be the same as, or different from, the others of B, B 1 , B 2 , and B 3 ;
- each of a and b is independently 0 or 1.
- the invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation.
- the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation, and suppressing oncogenicity.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound in an amount less than an amount which would cause toxicity in the patient.
- FIG. 1 Optimal concentration of IC-135 for inducement of terminal differentiation.
- FIG. 2 Comparison of HMBA and IC-135 on DS19 cells.
- FIGS. 3A and B Comparison of % cell committed for HMBA and IC-135 on V3.17 and DS19 cell lines.
- FIGS. 4A and B Comparison of B+% for HMBA and IC-135 on V3.17 and DS19 cell lines.
- the invention provides a class of compounds having the structure:
- each of A, A 1 , A 2 , A 3 , and A 4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom and wherein each of A, A 1 , A 2 , A 3 , and A 4 may independently be the same as, or different from, the others of A, A 1 , A 2 , A 3 , and A 4 ;
- each of R and R 1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure: ##STR4## each of R 2 and R 3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R 1 , R 2 and R 3 may independently be the same as, or different from, the others of R, R 1 , R 2 and R 3 ;
- each of R-A! and A 4 -R 1 ! have a dipolar moment greater than about 2.7 Debye units;
- each of B, B 1 , B 2 , and B 3 represents a nonpolar group which comprises at least 4 atoms in a chain, the termini of which chains are attached to A and A 1 , A 1 and A 2 , A 2 and A 3 , and A 3 and A 4 , respectively; wherein each such atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B 1 , B 2 , and B 3 may independently be the same as, or different from, the others of B, B 1 , B 2 , and B 3 ;
- each of a and b is independently 0 or 1.
- the compounds of the present invention are made up of two components.
- One component comprises a polar group, i.e. functional groups with significant dipole moments, such as amides, sulfoxides, amine oxides and related functional groups.
- the terminal portions of the compound each have dipole moments greater than about 2.7 debye units.
- the polar groups within the compound represented by -A 1 , -A 2 - and -A 3 -, have significant dipolar moments but not necessarily in excess of 2.7 debye units.
- the polar groups are carbonyl radicals or bivalent radicals of an amide, a sulfoxide or a amine oxide.
- Each polar group need not necessarily be the same as the other polar groups.
- the polar groups within the compound are the same as each other and the terminal polar groups are the same.
- all the polar groups are amide groups attached to the compound at the nitrogen atom or at the carbon atom of the carbonyl radical.
- the amide group may comprise one or more hydrocarbon substituents, such as a lower alkyl or alkenyl groups, including branched or unbranched groups.
- the term "lower alkyl or alkenyl group" is intended to include saturated and unsaturated hydrocarbon groups with 1 to about 5 carbon atoms.
- A is a carbonyl radical and R has the structure: ##STR6## wherein R 2 and R 3 each is hydrogen atom, a methyl group or a ethyl group.
- the compound also requires at least two nonpolar sections, designated B and B 1 , which are attached to and connect polar groups. Additional nonpolar sections may also be present, e.g. B 2 when a is 1 and B 3 when b is 1.
- the nonpolar sections may comprise linear saturated hydrocarbon chains, linear unsaturated hydrocarbon chains containing one or more double or triple bonds, or saturated or unsaturated hydrocarbon chains containing one or more lower alkyl or alkenyl groups or small carbocyclic rings as substituents.
- the nonpolar groups are hydrocarbon chains comprising 4 to 7 methylene groups, especially preferred are hydrocarbon chains containing 6 carbon atoms.
- the invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation in the cells.
- the contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably for about 4-5 days or longer.
- the method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effective by incubating the cells with the compound.
- the concentration of the compound in contact with the cells should be from about 0.5 to 25 mM, preferably from about 1 mM to about 5 mM.
- the invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells thereby inhibiting their proliferation, and suppressing oncogenicity.
- the method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other animals.
- the term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carinoma, breast carcinoma, or colorectal carcinoma.
- the administration of the compound to the patient may be effected orally or parenterally. To date, administration intravenously has proven to be effective.
- the administration of the compound must be preformed continuously for a prolonged period of time, such as for at least 3 days preferably more than 5 days.
- the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days.
- the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval.
- the amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient.
- the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound, i.e. about 1.5 mM.
- the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found that administration of the compound in an amount from about 5 gm/m 2 /day to about 30 gm/m 2 /day, particularly about 20 gm/m 2 /day, is effective for the practice of the invention without producing toxicity in the patient.
- the optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
- the invention also concerns a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and the compound in an amount less than an amount which if administered intravenously or orally to a patient would cause the patient's blood plasma concentration of the compound to exceed toxic levels.
- a pharmaceutically acceptable carrier such as sterile pyrogen-free water
- HMBA Hexamethylenebisacetamide
- IC-135 bis-Hexamethylenetriacetamide
- FIGS. 1, 2, 3A and B, and 4A and B are graphical representations of the data presented in Table 1.
- Table 2 shows cell counts for days 1, 2 and 5 and percentage of cells committed and benzidine reactive (B+) at day 5 for cell lines DS-19, V3.17 and DR-10 grown in 5 mM of HNBA and 0.5 to 3 mM of IC-135.
- IC-135 is more reactive in the tested cell lines at lower concentrations than HMBA.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a class of compounds and compositions thereof having the structure: ##STR1## wherein A is: ##STR2## The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an amount of the compound to selectively induce terminal differentiation. It also provides a method of treating a patient having a tumor characterized by proliferatoin of neoplastic cells comprising administration of an amount of the compound effective to inhibit proliferation and suppress oncogenicity of neoplastic cells.
Description
This is a continuation of U.S. Ser. No. 08/164,639, filed Dec. 9, 1993 (now abandoned), which is a continuation of U.S. Ser. No. 07/701,323, filed May 6, 1991, now abandoned, which is a continuation of U.S. Ser. No. 07/270,963, filed Nov. 14, 1988, now abandoned.
Throughout this application various publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms which normally govern proliferation and differentiation. For many years there have been two principal strategies for chemotherapeutic treatment of cancer: a) blocking hormone-dependent tumor cell proliferation by interference with the production or peripheral action of sex hormones; and b) killing cancer cells directly by exposing them to cytotoxic substances, which injure both neoplastic and normal cell populations. Relatively recently, cancer therapy is also being attempted by the induction of terminal differentiation of the neoplastic cells (10). In cell culture models differentiation has been reported by exposure of cells to a variety of stimuli, including: cyclic AMP and retinoic acid (1,2), aclarubicin and other anthracyclines (3), and polar planar compounds, of which the most extensively studied is hexamethylene bisacetamide (HMBA) (4-5, 9).
HMBA is capable of inducing phenotypic changes consistent with differentiation in a broad variety of cell lines (6). The characteristics of the drug-induced effect have been most extensively studied in the Friend murine erythroleukemia cell system (MELC) (6-9). MELC induction of differentiation is both time and concentration dependent. The minimum concentration required to demonstrate an effect in vitro in most strains is 2 to 3 mM; the minimum duration of continuous exposure generally required to induce differentiation in a substantial portion (>20%) of the population without continuing drug exposure is about 36 hours.
The present invention provides new chemical inducers which are 2-5 times more active then HMBA. It has unexpectedly been found that compounds having two or more nonpolar components connected by a polar group and having polar groups on the termini of the compound are effective inducers of terminal differentiation. For instance, bis-hexamethylene triacetamide, which comprises three acetamide groups connected by two six-carbon chains, has been found to be a potent inducer of terminal differentiation in MELC.
This new class of compounds of the present invention may be useful for selectively inducing terminal differentiation of neoplastic cells and therefore aid in treatment of tumors in patients.
The invention provides a class of compounds having the structure:
R-A!-B-A.sub.1 -B.sub.1 - A.sub.2 -B.sub.2 -!.sub.a A.sub.3 -B.sub.3 -!.sub.b A.sub.4 -R.sub.1 !
wherein each of A, A1, A2, A3, and A4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom and wherein each of A, A1, A2, A3, and A4 may independently be the same as, or different from, the others of A, A1, A2, A3, and A4 ;
wherein each of R and R1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure: ##STR3## each of R2 and R3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R1, R2 and R3 may independently be the same as, or different from, the others of R, R1, R2 and R3 ;
wherein each of R-A! and A4 -R1 ! have a dipolar moment greater than about 2.7 Debye units;
wherein each of B, B1, B2, and B3 represents a nonpolar group which comprises at least 4 atoms in a chain, the termini of which chains are attached to A and A1, A1 and A2, A2 and A3, and A3 and A4, respectively; wherein each such atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B1, B2, and B3 may independently be the same as, or different from, the others of B, B1, B2, and B3 ;
and wherein each of a and b is independently 0 or 1.
The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation.
Moreover, the invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells, thereby inhibiting their proliferation, and suppressing oncogenicity.
Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound in an amount less than an amount which would cause toxicity in the patient.
FIG. 1: Optimal concentration of IC-135 for inducement of terminal differentiation.
FIG. 2: Comparison of HMBA and IC-135 on DS19 cells.
FIGS. 3A and B: Comparison of % cell committed for HMBA and IC-135 on V3.17 and DS19 cell lines.
FIGS. 4A and B: Comparison of B+% for HMBA and IC-135 on V3.17 and DS19 cell lines.
The invention provides a class of compounds having the structure:
R-A!-B-A.sub.1 -B.sub.1 - A.sub.2 -B.sub.2 -!.sub.a A.sub.3 -B.sub.3 -!.sub.b A.sub.4 -R.sub.1 !
wherein each of A, A1, A2, A3, and A4 represent a polar group which comprises a nitrogen, sulfur or oxygen atom and wherein each of A, A1, A2, A3, and A4 may independently be the same as, or different from, the others of A, A1, A2, A3, and A4 ;
wherein each of R and R1 is a hydrogen atom; a lower alkyl, alkenyl, or alkynyl group; or a group having the structure: ##STR4## each of R2 and R3 being a hydrogen atom or a lower alkyl, alkenyl, or alkynyl group; and wherein each of R, R1, R2 and R3 may independently be the same as, or different from, the others of R, R1, R2 and R3 ;
wherein each of R-A! and A4 -R1 ! have a dipolar moment greater than about 2.7 Debye units;
wherein each of B, B1, B2, and B3 represents a nonpolar group which comprises at least 4 atoms in a chain, the termini of which chains are attached to A and A1, A1 and A2, A2 and A3, and A3 and A4, respectively; wherein each such atom is oxygen, nitrogen, carbon, or sulfur and wherein each of B, B1, B2, and B3 may independently be the same as, or different from, the others of B, B1, B2, and B3 ;
and wherein each of a and b is independently 0 or 1.
The compounds of the present invention are made up of two components. One component comprises a polar group, i.e. functional groups with significant dipole moments, such as amides, sulfoxides, amine oxides and related functional groups.
The terminal portions of the compound, represented by R-A and A4 -R1, each have dipole moments greater than about 2.7 debye units. The polar groups within the compound, represented by -A1, -A2 - and -A3 -, have significant dipolar moments but not necessarily in excess of 2.7 debye units. In the preferred embodiments, the polar groups are carbonyl radicals or bivalent radicals of an amide, a sulfoxide or a amine oxide. Each polar group need not necessarily be the same as the other polar groups. In the most preferred embodiments, the polar groups within the compound are the same as each other and the terminal polar groups are the same. Preferably, all the polar groups are amide groups attached to the compound at the nitrogen atom or at the carbon atom of the carbonyl radical. The amide group may comprise one or more hydrocarbon substituents, such as a lower alkyl or alkenyl groups, including branched or unbranched groups. The term "lower alkyl or alkenyl group" is intended to include saturated and unsaturated hydrocarbon groups with 1 to about 5 carbon atoms.
The embodiments where a and b are 0 and A is a carbonyl radical or a group having the structure: ##STR5## wherein R4 is a hydrogen atom or a lower alkyl or to alkenyl group, have proven to be the most useful embodiments to date.
Particularly preferred are compounds where a and b are 0, A is a carbonyl radical and R has the structure: ##STR6## wherein R2 and R3 each is hydrogen atom, a methyl group or a ethyl group.
The compound also requires at least two nonpolar sections, designated B and B1, which are attached to and connect polar groups. Additional nonpolar sections may also be present, e.g. B2 when a is 1 and B3 when b is 1. The nonpolar sections may comprise linear saturated hydrocarbon chains, linear unsaturated hydrocarbon chains containing one or more double or triple bonds, or saturated or unsaturated hydrocarbon chains containing one or more lower alkyl or alkenyl groups or small carbocyclic rings as substituents. In one of the preferred embodiments, the nonpolar groups are hydrocarbon chains comprising 4 to 7 methylene groups, especially preferred are hydrocarbon chains containing 6 carbon atoms.
The most preferred compounds for the practice of the present invention are those having the structures: ##STR7## wherein R is hydrogen or a methyl group and x is 5 or 6.
The invention also concerns a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable condition with an amount of the compound effective to selectively induce terminal differentiation in the cells.
The contacting must be performed continuously for a prolonged period of time, i.e. for at least 48 hours, preferably for about 4-5 days or longer.
The method may be practiced in vivo or in vitro. If the method is practiced in vitro, contacting may be effective by incubating the cells with the compound. The concentration of the compound in contact with the cells should be from about 0.5 to 25 mM, preferably from about 1 mM to about 5 mM.
The invention also concerns a method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of the compound effective to selectively induce terminal differentiation of such neoplastic cells thereby inhibiting their proliferation, and suppressing oncogenicity.
The method of the present invention is intended for the treatment of human patients with tumors. However, it is also likely that the method would be effective in the treatment of tumors in other animals. The term tumor is intended to include any cancer caused by the proliferation of neoplastic cells, such as lung cancer, acute lymphoid myeloma, bladder melanoma, renal carinoma, breast carcinoma, or colorectal carcinoma. The administration of the compound to the patient may be effected orally or parenterally. To date, administration intravenously has proven to be effective. The administration of the compound must be preformed continuously for a prolonged period of time, such as for at least 3 days preferably more than 5 days. In the most preferred embodiments, the administration is effected continuously for at least 10 days and is repeated at intervals wherein at each interval the administration is continuously effected for at least 10 days. For example, the administration may be effected at intervals as short as 5-10 days, up to about 25-35 days and continuously for at least 10 days during each such interval.
The amount of the compound administered to the patient is less than an amount which would cause toxicity in the patient. In the preferred embodiments, wherein the compound has the structure: ##STR8## the amount of the compound which is administered to the patient is less than the amount which causes a concentration of the compound in the patient's plasma to equal or exceed the toxic level of the compound, i.e. about 1.5 mM. Preferably, the concentration of the compound in the patient's plasma is maintained at about 1.0 mM. It has been found that administration of the compound in an amount from about 5 gm/m2 /day to about 30 gm/m2 /day, particularly about 20 gm/m2 /day, is effective for the practice of the invention without producing toxicity in the patient. The optimal amount of the compound which should be administered to the patient in the practice of the present invention will depend on the particular compound used and the type of cancer being treated.
The invention also concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier, such as sterile pyrogen-free water, and the compound in an amount less than an amount which if administered intravenously or orally to a patient would cause the patient's blood plasma concentration of the compound to exceed toxic levels.
The invention is illustrated in the Experimental Detail section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.
Experimental Details:
Manufacture of bis-Hexamethylenetriacetamide
A solution of 19.8 gm commercial bis-hexamethylenetriamine in 500 ml of 1,4-dioxane was made up at room temperature under argon. Then 44.8 ml. of triethylamine was added, and 20.3 ml. of acetyl chloride was slowly added with stirring. After two hours of stirring at room temperature the triethylamine hydrochloride was removed by filtration and the filtrate was concentrated in vacuo. The product triacetyl compound was isolated as a clear viscous oil at about 90% yield by chromatography on basic alumina using isopropanol/ethyl acetate/dichloromethane in the ratio 2/3/5. On thin layer plates of basic alumina with this solvent mixture the product had an Rf of ca. 0.6.
The mass spectrum (chemical ionization, NH3 carrier) showed peaks at 342 (100%, M+1), 227 (10%) and 115 (22%). The infrared spectrum (thin film on NaCl) had bands at 3288, 2931, 2858, 1627, 1560, 1437, 1373, and 1292 cm-1. In the proton NMR (CDCl3) the acetyl groups appeared at δ2.06 (3 H) and 1.96 (6 H) as singlets, the two NH protons appeared at δ6.10 as a broad signal, while the methylene protons appeared as multiplets with the expected intensities in the regions of δ3.12 to 3.30 and 1.21 to 1.54. ##STR9##
Induced Terminal Differentiation in Cell Cultures
Cell cultures were grown in the presence of different concentrations of Hexamethylenebisacetamide (HMBA) ##STR10## and bis-Hexamethylenetriacetamide (IC-135).
At 1, 2 and 5 days, the cell densities and the percentage of cells that were benzidine reactive (B+) were measured. Table 1 shows the cell densities, B+%, and percent of cells commited for cell lines DS19 and V3.17 grown in 1 m to 5 mM of HMBA and IC-135. FIGS. 1, 2, 3A and B, and 4A and B are graphical representations of the data presented in Table 1.
Table 2 shows cell counts for days 1, 2 and 5 and percentage of cells committed and benzidine reactive (B+) at day 5 for cell lines DS-19, V3.17 and DR-10 grown in 5 mM of HNBA and 0.5 to 3 mM of IC-135.
As can be seen in the Tables and Figures, IC-135 is more reactive in the tested cell lines at lower concentrations than HMBA.
TABLE 1
__________________________________________________________________________
24 h 48 h 120 h
cell cell cell commitment
count
B+ count
B+ count
B+ 24 h
48 h
__________________________________________________________________________
HMBA 1 mM
DS19
0.4
0-1 1.0
0-1
3.0 × 10.sup.6
8% 0-1
6-8
V.sub.3 17
0.38
8-9 0.8
33%
2.8 58%
30%
43%
2 mM
DS19
0.42
0-1 0.9
0-1
2.9 64%
0-1
71%
V.sub.3 17
0.4
7-9 0.8
72%
2.6 89%
39%
79%
3 mM
DS19
0.4
0-1 0.9
2 2.8 82%
0-1
81%
V.sub.3 17
0.3
9-10
0.4
80%
1.8 91%
77%
94%
4 mM
DS19
0.3
0-1 0.8
11%
2.6 94%
4% 92%
V.sub.3 17
0.28
9-13
0.4
88%
1.6 96%
80%
99%
5 mM
DS19
0.23
0-1 0.5
14%
2.4 98%
6% 96%
V.sub.3 17
0.22
9-14
0.5
89%
1.6 99%
83%
98%
IC-135
1 mM
DS19
0.3
0-1 0.6
0-1
1.6 69%
0-1
71%
V.sub.3 17
0.3
8-9 0.6
83%
1.3 89%
58%
89%
2 mM
DS19
0.3
0-1 0.5
0-1
1.3 79%
1-2
87%
V.sub.3 17
0.29
7-6 0.4
88%
1.3 94%
70%
95%
3 mM
DS19
0.27
0-1 0.4
0-1
1.3 86%
5-4
91%
V.sub.3 17
0.12
8-6 0.3
89%
0.9 96%
76%
97%
4 mM
DS19
0.13
0-1 0.2
0-1
0.6 78%
2-1
79%
V.sub.3 17
0.18
6-8 0.19
34%
0.5 79%
44%
81%
5 mM
DS19
0.12
0 0.13
0-1
0.4 -- 8% --
V.sub.3 17
0.12
8-11
0.12
0-1
0.3 -- 0-1
--
CONTROL 0.4
5-9 1.0
0-1
3.1 × 10.sup.6
0-1
0-1
0-1
IC-135 50 mM Stock
1 mM 40 λ
5 mM 200 λ
HMBA 200 mM Stock
1 mM 10 λ
5 mM. 50 λ
__________________________________________________________________________
TABLE 2
______________________________________
TESTING OF IC-135 ON DIFFERENT MELC LINES
5th Day
1st 2nd Cell 5th (5 day
DS-1g Day Day Count B.sup.+
commitment)
______________________________________
Control 0.38 1.1 2.8 0-1 0-1
5 mM HMBA
0.2 0.5 2.0 91-90 88-88
0.5 mM IC-135
0.38 1 2.1 41-49 31-28
1 mM IC-135
0.33 0.8 1.4 72-74 51-58
2 mM IC-135
0.2 0.5 1.3 80-80 78-76
3 mM IC-135
0.2 0.5 1.2 87-88 81-80
______________________________________
1st 2nd 5th 5th (5 day
V3-17 Day Day Day B.sup.+
commitment)
______________________________________
Control 0.4 1.2 2.9 3-6 0-1
5 mM HMBA
0.23 0.5 1.6 98-99 99-98
0.5 mM IC-135
0.4 0.6 2.7 40-49 36-34
1 mM IC-135
0.31 0.44 1.3 89-83 89-91
2 mM IC-135
0.21 0.4 1.0 96-91 92-94
3 mM IC-135
0.23 0.3 0.9 98-97 99-99
______________________________________
1st 2nd 5th 5th (5th day
DR-10 Day Day Day B.sup.+
commitment)
______________________________________
Control 0.41 1.0 2.9 0-1 0-0
5 mM HMBA
0.3 0.48 2.1 90-89 1-4
0.5 mM IC-135
0.4 0.62 1.9 44-39 0-0
1 mM IC-135
0.32 0.48 1.4 70-74 0-1
2 mM IC-135
0.2 0.41 1.2 79-81 0-2
3 mM IC-135
0.2 0.40 1.2 88-86 1-3
______________________________________
References:
1. Breitman, T. R., Selonick, S. E., and Collins, S. J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA., 77:2936-2940, 1980.
2. Olsson, I. L., and Breitman, T. R. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3':5'-monophosphate-inducing agents. Cancer Res., 42:3924-3927, 1982.
3. Schwartz, E. L., and Sartorelli, A. C. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res., 42:2651-2655, 1982.
4. Marks, P. A., and Rifkind, R. A. Erythroleukemic differentiation. Annu. Rev. Biochem., 47:419-448, 1978.
5. Friend, C., Scher, W., Holland, J., and Sato, T. Hemoglobin synthesis in murine erythroleukemia cells in vitro: stimulation of erythroid differentiation by dimethylsulfoxide. Proc. Natl. Acad. Sci. USA, 68:378-382, 1971.
6. Marks, P. A., Sheffery, M., and Rifkind, R. A. Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res. 47:659-666, 1987.
7. Fibach, E., Reuben, R. C., Rifkind, R. A., and Marks, P. A. Effect of hexamethylene bisacetaxide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res., 37:440-444, 1977.
8. Reuben, R. C., Khanna, P. L., Gazitt, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. Inducers of erythroleukemic differentiation. Relationship of structure to activity among planar-polar compounds. J. Biol. Chem., 253:4124-4128, 1978.
9. Marks, P. A. and Rifkind, R. A. Hexamethylene Biscetamide Induced Differentiation of Transformed Cells: Molecular and Cellular Effects and Therapeutic Application. International Journal of Cell Cloning, 6:230-240, 1988.
10. Sporn, M. B., Roberts, A. B., Driscoll, J. S.:
Principles of Cancer Biology: Growth Factor and Differentiation. In: Cancer Principles and Practic of Oncology Vol. 1: 2nd Edition. Eds. V. de Vita, S. Hellman and S. Rosenberg. Publ.: J.B. Lippincott Company, pgs. 49-65, 1985.
Claims (17)
1. A compound having the structure: ##STR11## wherein each of R2 and R3 is a hydrogen atom or a methyl, ethyl, or propyl group and is the same or different, and wherein each of y and y1 is independently 4, 5, 6 or 7;
wherein A1 is ##STR12## wherein R5 is a hydrogen atom or a methyl, ethyl or propyl group.
2. A compound of claim 1 having the structure: ##STR13## wherein each of y and y1 is independently 5 or 6.
3. A compound of claim 2, wherein A1 is ##STR14##
4. A method of treating a patient having a tumor characterized by proliferation of neoplastic cells which comprises administering to the patient an amount of a compound of claim 1 effective to selectively induce terminal differentiation of such neoplastic cells and thereby inhibit their proliferation.
5. The method of claim 4, wherein the compound has the structure: ##STR15## wherein each of R2 and R3 is independently hydrogen, methyl, ethyl or propyl; wherein A1 is ##STR16## and wherein each of y and y1 is independently 5, 6 or 7.
6. The method of claim 5, wherein the compound has the structure: ##STR17##
7. The method of claim 4, wherein the administering is effected once continuously for at least 5 days.
8. The method of claim 7, wherein the administering is effected once continuously for at least 10 days.
9. The method of claim 4, wherein the administering is effected at intervals of 5-35 days and continuously for at least 5 days during each such interval.
10. The method of claim 4, wherein the amount of the compound is less than an amount which causes toxicity in the patient.
11. The method of claim 10, wherein the amount of the compound is from about 1 gm/m2 /day to about 30 gm/m2 /day.
12. The method of claim 4, wherein the tumor is a lung cancer, acute lymphoid myeloma, bladder myeloma, renal carcinoma, breast carcinoma or colorectal carcinoma.
13. The method of claim 4, wherein the administering is effected intravenously.
14. The method of claim 4, wherein the administering is effected orally.
15. A method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells which comprises contacting the cells under suitable conditions with an amount of a compound effective to selectively induce terminal differentiation, wherein the compound has the structure: ##STR18## wherein each of R2 and R3 is a hydrogen atom or a methyl, ethyl or propyl group and each being the same or different;
wherein A1 is ##STR19## and wherein each of y and y1 is independently 5, 6 or 7.
16. A method of claim 15, wherein the amount of the compound is from about 0.1 to about 10 mM.
17. A compound of clam 1, wherein R2 is a hydrogen atom, R3 is an ethyl group and each of y and y1 is independently 4, 5 or 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/485,620 US5773474A (en) | 1988-11-14 | 1995-06-07 | Potent inducers of terminal differentiation and method of use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27096388A | 1988-11-14 | 1988-11-14 | |
| US70132391A | 1991-05-06 | 1991-05-06 | |
| US16463993A | 1993-12-09 | 1993-12-09 | |
| US08/485,620 US5773474A (en) | 1988-11-14 | 1995-06-07 | Potent inducers of terminal differentiation and method of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16463993A Continuation | 1988-11-14 | 1993-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5773474A true US5773474A (en) | 1998-06-30 |
Family
ID=23033594
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/374,343 Expired - Lifetime US5055608A (en) | 1988-11-14 | 1989-06-30 | Novel potent inducers of thermal differentiation and method of use thereof |
| US08/485,620 Expired - Fee Related US5773474A (en) | 1988-11-14 | 1995-06-07 | Potent inducers of terminal differentiation and method of use thereof |
| US08/485,619 Expired - Lifetime US5668179A (en) | 1988-11-14 | 1995-06-07 | Potent inducers of terminal differentiation and method of use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/374,343 Expired - Lifetime US5055608A (en) | 1988-11-14 | 1989-06-30 | Novel potent inducers of thermal differentiation and method of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/485,619 Expired - Lifetime US5668179A (en) | 1988-11-14 | 1995-06-07 | Potent inducers of terminal differentiation and method of use thereof |
Country Status (1)
| Country | Link |
|---|---|
| US (3) | US5055608A (en) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030013176A1 (en) * | 1999-09-08 | 2003-01-16 | Nikola Pavletich | Crystal structure of a deacetylase and inhibitors thereof |
| US6511990B1 (en) | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| WO2003032921A2 (en) | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| WO2003075839A2 (en) | 2002-03-04 | 2003-09-18 | Aton Pharma, Inc. | Methods of inducing terminal differentiation |
| US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
| US20040018968A1 (en) * | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| US20040075230A1 (en) * | 2002-10-17 | 2004-04-22 | Teng-Hsiang Lin | Self-movable vehicle |
| US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20040142859A1 (en) * | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| US20040235733A1 (en) * | 2003-02-27 | 2004-11-25 | Steffan Joan S. | Methods and reagents for reducing polyglutamine toxicity |
| US20040266818A1 (en) * | 2003-04-01 | 2004-12-30 | Ronald Breslow | Hydroxamic acid compounds and methods of use thereof |
| US20050227915A1 (en) * | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
| US20050288227A1 (en) * | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US20060292594A1 (en) * | 2005-03-01 | 2006-12-28 | Regents Of The University Of Michigan | HDAC inhibitors that promote BRM expression and BRM related diagnostics |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20070190022A1 (en) * | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
| US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
| US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
| US20080124403A1 (en) * | 2006-06-08 | 2008-05-29 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
| US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US20090305956A1 (en) * | 2006-04-24 | 2009-12-10 | Gloucester Pharmaceuticals, Inc. | Treatment of Ras-Expressing Tumors |
| US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
| US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
| US20100324034A1 (en) * | 2007-02-08 | 2010-12-23 | Hazuda Daria J | Methods of Using SAHA for Treating HIV Infection |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| EP1117778A2 (en) * | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| WO2003083066A2 (en) | 2002-03-27 | 2003-10-09 | Immunex Corporation | Methods for increasing polypeptide production |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801748A (en) * | 1985-03-08 | 1989-01-31 | Osaka University | Catalytic process for preparing amide from nitrile, amine and water |
| US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
-
1989
- 1989-06-30 US US07/374,343 patent/US5055608A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/485,620 patent/US5773474A/en not_active Expired - Fee Related
- 1995-06-07 US US08/485,619 patent/US5668179A/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801748A (en) * | 1985-03-08 | 1989-01-31 | Osaka University | Catalytic process for preparing amide from nitrile, amine and water |
| US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
Non-Patent Citations (7)
| Title |
|---|
| Morrison, R.T. and Boyd, R.N., Organic Chemistry (3rd ed. Allyn and Bacon) (Boston) (1973) p. 755. * |
| Reuben, R. C., et al., Inducers of Erythroleukemic Differentiation J. Biol. Chem. (1978) 253 (12): 4214 4218. * |
| Reuben, R. C., et al., Inducers of Erythroleukemic Differentiation J. Biol. Chem. (1978) 253 (12): 4214-4218. |
| Reuben, Robera C., et al., A New Group of Potent Inducers Of Differentiation in Murine Erythroleukemia Cells. Proc. Natl. Academy Sci. USA (1976) 73(3): 862 866. * |
| Reuben, Robera C., et al., A New Group of Potent Inducers Of Differentiation in Murine Erythroleukemia Cells. Proc. Natl. Academy Sci. USA (1976) 73(3): 862-866. |
| Tanaka, M., et al., Induction of Erythroid Differentation in Murine Virus Infected Erythroleukemia Cells by Highly Polar Compounds. Proc. Natl. Acad. Sci. USA (1975) 72(3) : 1003 1006. * |
| Tanaka, M., et al., Induction of Erythroid Differentation in Murine Virus Infected Erythroleukemia Cells by Highly Polar Compounds. Proc. Natl. Acad. Sci. USA (1975) 72(3) : 1003-1006. |
Cited By (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7126001B2 (en) | 1999-09-08 | 2006-10-24 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US20070010536A1 (en) * | 1999-09-08 | 2007-01-11 | Ronald Breslow | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US7345174B2 (en) | 1999-09-08 | 2008-03-18 | Sloan-Kettering Institute For Cancer Research | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US20070087427A1 (en) * | 1999-09-08 | 2007-04-19 | Nikola Pavletich | Crystal structure of a deacetylase and inhibitors thereof |
| US20070100559A1 (en) * | 1999-09-08 | 2007-05-03 | Nikola Pavletich | Crystal structure of a deacetylase and inhibitors thereof |
| US6511990B1 (en) | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US7124068B2 (en) | 1999-09-08 | 2006-10-17 | Sloan-Kettering Institute For Cancer Research | Crystal structure of a deacetylase and inhibitors thereof |
| US20060241129A1 (en) * | 1999-09-08 | 2006-10-26 | Ronald Breslow | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| US20030013176A1 (en) * | 1999-09-08 | 2003-01-16 | Nikola Pavletich | Crystal structure of a deacetylase and inhibitors thereof |
| US20050227915A1 (en) * | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
| US20110124731A1 (en) * | 2001-10-16 | 2011-05-26 | Sloan-Kettering Institute For Cancer Research | Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors |
| WO2003032921A3 (en) * | 2001-10-16 | 2003-10-30 | Sloan Kettering Inst Cancer | Treatment of neurodegenerative diseases and cancer of the brain |
| EP2269609A3 (en) * | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| WO2003032921A2 (en) | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| EP2269609A2 (en) | 2001-10-16 | 2011-01-05 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| US7879865B2 (en) | 2001-10-16 | 2011-02-01 | Sloan-Kettering Institute For Cancer Research | Treatment of cancer of the brain using histone deacetylase inhibitors |
| US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
| US20050288227A1 (en) * | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| US20060009526A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
| US20060009527A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
| US20100210729A1 (en) * | 2002-03-04 | 2010-08-19 | Richon Victoria M | Methods of inducing terminal differentiation |
| US7851509B2 (en) | 2002-03-04 | 2010-12-14 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| WO2003075839A2 (en) | 2002-03-04 | 2003-09-18 | Aton Pharma, Inc. | Methods of inducing terminal differentiation |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US8101663B2 (en) | 2002-03-04 | 2012-01-24 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US8067472B2 (en) | 2002-03-04 | 2011-11-29 | Merck Hdac Research, Llc | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| EP2322160A1 (en) | 2002-03-04 | 2011-05-18 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20040127523A1 (en) * | 2002-03-04 | 2004-07-01 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
| EP2266552A2 (en) | 2002-03-04 | 2010-12-29 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US7847122B2 (en) | 2002-03-04 | 2010-12-07 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
| US20080114069A1 (en) * | 2002-03-04 | 2008-05-15 | Richon Victoria M | Methods of inducing terminal differentiation |
| US7375137B2 (en) | 2002-03-04 | 2008-05-20 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
| US20080119562A1 (en) * | 2002-03-04 | 2008-05-22 | Richon Victoria M | Methods of Inducing Terminal Differentiation |
| US20100168242A1 (en) * | 2002-03-04 | 2010-07-01 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
| US7732490B2 (en) | 2002-03-04 | 2010-06-08 | Merck Hdac Research, Llc | Methods of treating cancer |
| US7399787B2 (en) | 2002-03-04 | 2008-07-15 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
| US20080194692A1 (en) * | 2002-03-04 | 2008-08-14 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
| US20080228005A1 (en) * | 2002-03-04 | 2008-09-18 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
| US20080249179A1 (en) * | 2002-03-04 | 2008-10-09 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US7652069B2 (en) | 2002-03-04 | 2010-01-26 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| EP2082737A2 (en) | 2002-03-04 | 2009-07-29 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| US20040018968A1 (en) * | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| US20090054720A1 (en) * | 2002-04-15 | 2009-02-26 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| US20040142859A1 (en) * | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| US20040075230A1 (en) * | 2002-10-17 | 2004-04-22 | Teng-Hsiang Lin | Self-movable vehicle |
| US20040235733A1 (en) * | 2003-02-27 | 2004-11-25 | Steffan Joan S. | Methods and reagents for reducing polyglutamine toxicity |
| US7199134B2 (en) | 2003-04-01 | 2007-04-03 | Sloan-Kettering Institute For Cancer Research | Hydroxamic acid compounds and methods of use thereof |
| US20040266818A1 (en) * | 2003-04-01 | 2004-12-30 | Ronald Breslow | Hydroxamic acid compounds and methods of use thereof |
| US7799803B2 (en) | 2003-04-01 | 2010-09-21 | The Trustees Of Columbia University In The City Of New York | Hydroxamic acid compounds and methods of use thereof |
| US20070155785A1 (en) * | 2003-04-01 | 2007-07-05 | Ronald Breslow | Hydroxamic acid compounds and methods of use thereof |
| US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| EP2201947A2 (en) | 2003-08-26 | 2010-06-30 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
| EP2226072A1 (en) | 2003-08-29 | 2010-09-08 | Aton Pharma, Inc. | Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer |
| US20070190022A1 (en) * | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
| US20100273732A1 (en) * | 2003-08-29 | 2010-10-28 | Bacopoulos Nicholas G | Combination methods of treating cancer |
| US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
| US20060292594A1 (en) * | 2005-03-01 | 2006-12-28 | Regents Of The University Of Michigan | HDAC inhibitors that promote BRM expression and BRM related diagnostics |
| US7604939B2 (en) | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
| US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
| US8288440B2 (en) | 2005-05-20 | 2012-10-16 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| US8450372B2 (en) | 2005-05-20 | 2013-05-28 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| US8093295B2 (en) | 2005-05-20 | 2012-01-10 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
| US20100119596A1 (en) * | 2005-05-20 | 2010-05-13 | Jeannie Chow Wong | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
| US20090247549A1 (en) * | 2005-11-04 | 2009-10-01 | Frankel Stanley R | Methods of using saha and bortezomib for treating cancer |
| US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
| US20090305956A1 (en) * | 2006-04-24 | 2009-12-10 | Gloucester Pharmaceuticals, Inc. | Treatment of Ras-Expressing Tumors |
| US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
| US20080124403A1 (en) * | 2006-06-08 | 2008-05-29 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| US9259452B2 (en) | 2006-06-08 | 2016-02-16 | Gelgene Corporation | Deacetylase inhibitor therapy |
| US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
| US20100324034A1 (en) * | 2007-02-08 | 2010-12-23 | Hazuda Daria J | Methods of Using SAHA for Treating HIV Infection |
Also Published As
| Publication number | Publication date |
|---|---|
| US5055608A (en) | 1991-10-08 |
| US5668179A (en) | 1997-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5773474A (en) | Potent inducers of terminal differentiation and method of use thereof | |
| US5840960A (en) | Potent inducers of terminal differentiation and method of use thereof | |
| US5175191A (en) | Potent inducers of terminal differentiation and methods of use thereof | |
| US3261859A (en) | Basically substituted phenyl acetonitrile compounds | |
| AU668696B2 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
| US5677349A (en) | Agmatine for the treatment of neurotrauma and neurodegenerative diseases | |
| ES2210293T3 (en) | NEW POWERFUL INDUCERS OF THE TERMINAL DIFFERENTIATION AND METHODS OF USE. | |
| ATE33838T1 (en) | THIAZOLIDE DERIVATIVES, THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM. | |
| FR2680366B1 (en) | NOVEL ARYLETHYLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| OA09482A (en) | "New derivatives with a naphthalene structure, their preparation process and the pharmaceutical compositions which contain them". | |
| Marks et al. | Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential. | |
| US4882346A (en) | Chemical differentiating agents | |
| AU643248B2 (en) | Novel potent inducers of terminal differentiation and method of use thereof | |
| Citarella et al. | Activity of a Novel Anthracenyl Bishydrazone, 9, 10-Anthracenedicarboxaldehyde Bis [(4, 5-dihydro-1 H-imidazol-2-yl) hydrazone] Dihydrochloride, against Experimental Tumors in Mice | |
| WO1991000257A1 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
| EP3904330A1 (en) | Ethylenediamine compound and use thereof | |
| DE69318046T2 (en) | Anti-cancer benzaldehyde compounds | |
| CA2482035A1 (en) | Novel sodium channel blockers | |
| WO1990009092A2 (en) | Novel potent inducers of terminal differentiation and method of use thereof | |
| DE68910090T2 (en) | Use of heterocyclic amides to prevent tumor metastasis. | |
| US6518312B2 (en) | Immune enhancement | |
| JPH0789920A (en) | New compound | |
| RU1774624C (en) | 1-propyl-2-oxo-4-hydroxyquinoline-3-carboxylic acid diethylaminoethylamide hydrochloride showing anesthetic, antiarrhythmic, antioxidant, antimicrobial and fungicidal activity | |
| EP0705606B1 (en) | Use of 5-Thia-1,4-diazabicyclo [4.2.0] octane-3,8-dioxo compounds in antitumor therapy | |
| DE1966174C3 (en) | Aryl esters of 4-aminomethylbenzoic acid, their pharmaceutically acceptable salts, processes for the preparation of these compounds and pharmaceutical preparations containing these compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: R283); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100630 |
|
| AS | Assignment |
Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, NEW Free format text: CHANGE OF ADDRESS OF ASSIGNEE;ASSIGNORS:BRESLOW, RONALD;MARKS, PAUL A.;RIFKIND, RICHARD A.;SIGNING DATES FROM 19881104 TO 19881110;REEL/FRAME:024864/0576 |